X0306 4 2021-02-17 0 0001538210 NexImmune, Inc. NEXI 0001643070 Roemer Alan S. C/O NEXIMMUNE, INC. 9119 GAITHER ROAD GAITHERSBURG MD 20877 1 0 0 0 Common Stock 2021-02-17 4 C 0 85016 A 85016 D Common Stock 2021-02-17 4 C 0 4110 A 89126 D Common Stock 2021-02-17 4 C 0 26590 A 115716 D Common Stock 2021-02-17 4 C 0 12268 A 127984 D Series A Preferred Stock 2021-02-17 4 C 0 85016 D Common Stock 85016 0 D Series A2 Preferred Stock 2021-02-17 4 C 0 4110 D Common Stock 4110 0 D Series A3 Preferred Stock 2021-02-17 4 C 0 26590 D Common Stock 26590 0 D Convertible Promissory Note 2021-02-17 4 C 0 104570.00 D Common Stock 12268 0 D The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. Not applicable. /s/ Ilse Johnson, Attorney-in-fact 2021-02-19